Savara (SVRA) said Thursday it has launched its aPAP ClearPath dried blood spot test in the US.
The test is designed to help obtain a diagnosis of aPAP, a rare autoimmune lung disease, through a finger-prick blood sample, the company said.
The DBS test has achieved 100% sensitivity and specificity in a group of individuals with aPAP autoantibody status, Savara said.
Shares were almost 2% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.